Aggressive fibromatosis is a type of musculoskeletal fibromatosis. While it is a non-metastasising fibrous lesion, it is thought to be a true neoplasm that arises from the fascial and musculoaponeurotic coverings, sometimes at the site of a traumatic or post-surgical scar.
The term aggressive fibromatosis is occasionally used synonymously with desmoid tumors by some authors 5. This article will focus in the musculoskeletal presentation of this tumor; for the abdominal presentation, please refer to the latter.
According to one the study, the mean age at presentation is ~40 7. There may be a slight female predilection (male to female ratio of 1:1.2).
Being non-encapsulated, poorly circumscribed, and infiltrative, aggressive fibromatosis grows insidiously and invades locally. The lesions may become quite large and adhere to neighbouring structures, such as neurovascular bundles. The lesions grossly resemble scar tissue and are composed of well-differentiated fibroblasts embedded in an abundant collagenous matrix with increased cellularity at the periphery. Cytologic features of malignancy are lacking. Its exact cause is unknown.
Recognised associations include:
- surgical or accidental trauma
- oestrogenic hormone use
- Gardner syndrome
- familial adenomatous polyposis
Radiographs may show a soft-tissue mass, localised periosteal thickening, or direct bony destruction/invasion 4.
Signal characteristics of the lesion include 7:
- T1: homogeneously isointense or mildly hyperintense
- T2/STIR: high heterogeneous signal
- T1 C+ (Gd): typically enhances avidly
- GE: peripheral areas of smooth low signal intensity that do not represent calcification (check radiographs) or hemorrhage (check gradient images/scouts for blooming) are characteristic
May show arterial stretching, neovascularity, and tumor staining 4.
Treatment and prognosis
It does not have any propensity for metastasis although it can aggressively invade structures. The optimal management for aggressive fibromatosis depends on tumor location and extent. Surgical resection may be offered although the likelihood of local recurrence after surgery is high, particularly if margins are positive. Moderate-dose radiotherapy alone for gross disease or after a microscopically incomplete resection yields local control rates of approximately 75-80% 3. Treatment with pharmacologic agents results in objective response rates of approximately 40-50%.
- 1. Hudson TM, Bertoni F, Enneking WF. Scintigraphy of aggressive fibromatosis. Skeletal Radiol. 1985;13 (1): 26-32. - Pubmed citation
- 2. Campbell AN, Chan HS, Daneman A et-al. Aggressive fibromatosis in childhood. Computed tomographic findings in three patients. J Comput Tomogr. 1983;7 (1): 109-13. - Pubmed citation
- 3. Mendenhall WM, Zlotecki RA, Morris CG et-al. Aggressive fibromatosis. Am. J. Clin. Oncol. 2005;28 (2): 211-5. Am. J. Clin. Oncol. (link) - Pubmed citation
- 4. Ackman JB, Whitman GJ, Chew FS. Aggressive fibromatosis. AJR Am J Roentgenol. 1994;163 (3): 544. AJR Am J Roentgenol (citation) - Pubmed citation
- 5. Nuyttens JJ, Rust PF, Thomas CR et-al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer. 2000;88 (7): 1517-23. - Pubmed citation
- 6. Robbin MR, Murphey MD, Temple HT et-al. Imaging of musculoskeletal fibromatosis. Radiographics. 21 (3): 585-600. Radiographics (full text) - Pubmed citation
- 7. Lee JC, Thomas JM, Phillips S et-al. Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol. 2006;186 (1): 247-54. doi:10.2214/AJR.04.1674 - Pubmed citation
- 8. Mcdonald ES, Yi ES, Wenger DE. Best cases from the AFIP: extraabdominal desmoid-type fibromatosis. Radiographics. 28 (3): 901-6. doi:10.1148/rg.283075169 - Pubmed citation
- 9. Murphey MD, Ruble CM, Tyszko SM et-al. From the archives of the AFIP: musculoskeletal fibromatoses: radiologic-pathologic correlation. Radiographics. 2009;29 (7): 2143-73. doi:10.1148/rg.297095138 - Pubmed citation